Skip to main content

Ethicon Physiomesh Bellwether Trial Date Delayed By 75 Days

Ethicon Physiomesh Bellwether Trial Date Delayed By 75 Days

Ethicon Physiomesh Bellwether Trial Date Delayed By 75 Days

Introduction

According to an order issued on September 11 by U.S. District Judge Richard Story presiding over all Ethicon physiomesh cases, the discovery deadlines have been extended for two and a half months; this will push the start of the first bellwether trial date until the end of 2019 or early 2020.

The initial discovery pool concerning the transvaginal mesh complications was expected to be finalized by December 2018, but that selection would now be delayed until mid-February 2019. Each side has been ordered to submit a proposal regarding the manner of the trial, order of the selection of plaintiffs and specific timing of trials earliest by mid-July 2019. The court will consider challenges to the admissibility of expert witness testimony and dispositive motions by 2019 end.

Ethicon Pelvic Mesh lawsuits claiming design defect complications and failure to warn allegations are centralized as a part of a multidistrict litigation (MDL No. 2327; In Re: Ethicon, Inc., Pelvic Repair System Products Liability Litigation) overlooked by U.S. District Judge Joseph R. Goodwin in the Southern District of West Virginia.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.